← boothcheck

Is HQY overvalued?

boothcheck doesn't label HQY overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, HQY is priced for growth of +14.4%, and an operating margin near 6.4% versus the 26.6% it earns today. Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium). The more the price assumes beyond what HEALTHEQUITY, INC. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from HEALTHEQUITY, INC.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 29, 2026.

Implied growth+14.4%
For about
Margin needed6.4%
Margin today26.6%
Price vs asset value2.95x
Price vs earnings power2.18x
Price vs peer multiples1.31x
Price vs forward growth0.76x
Read the full HQY report →
Get boothcheck's read on what HQY's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.